U.S. markets closed
  • S&P Futures

    3,653.75
    +30.50 (+0.84%)
     
  • Dow Futures

    29,870.00
    +241.00 (+0.81%)
     
  • Nasdaq Futures

    12,384.00
    +107.00 (+0.87%)
     
  • Russell 2000 Futures

    1,841.30
    +21.20 (+1.16%)
     
  • Crude Oil

    45.04
    -0.30 (-0.66%)
     
  • Gold

    1,784.60
    +3.70 (+0.21%)
     
  • Silver

    22.88
    +0.29 (+1.27%)
     
  • EUR/USD

    1.1959
    +0.0024 (+0.20%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3352
    +0.0020 (+0.15%)
     
  • USD/JPY

    104.3290
    +0.0050 (+0.00%)
     
  • BTC-USD

    19,596.41
    +86.53 (+0.44%)
     
  • CMC Crypto 200

    384.60
    +20.00 (+5.49%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,808.06
    +374.44 (+1.42%)
     

AnaptysBio (ANAB) Jumps: Stock Rises 7.7%

Zacks Equity Research
·2 min read

AnaptysBio, Inc. ANAB was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 41.2% in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

AnaptysBio currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

AnaptysBio, Inc. Price

AnaptysBio, Inc. Price
AnaptysBio, Inc. Price

AnaptysBio, Inc. price | AnaptysBio, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is QIAGEN N.V. QGEN, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
 
AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research